Patient demographics
| . | No abatacept (n = 14) . | Abatacept (n = 50) . | P value . |
|---|---|---|---|
| Age, median (range), y | 7.3 (2-13.8) | 6.5 (2-13) | .5 |
| Preparative regimen, n (%) | |||
| Busulfan/fludarabine/thiotepa | 14 (100) | 50 (100) | 1.0 |
| HLA match, n (%) | .9 | ||
| Full match | 11 (78) | 40 (80) | |
| Single antigen mismatch | 3 (22) | 10 (20) | |
| Donor relation, n (%) | .9 | ||
| Unrelated | 5 (35) | 19 (38) | |
| Related | 9 (65) | 31 (62) | |
| Stem cell source, n (%) | .9 | ||
| Bone marrow | 12 (85) | 40 (80) | |
| Umbilical cord blood | 1 (7.5) | 0 (0) | |
| Bone marrow + cord blood | 1 (7.5) | 10 (20) | |
| Pre-HSCT median LIC by MRI T2∗ (range), μg/g | 4471 (1658-6800) | 4395 (1666-9742) | .7 |
| Risk stratification, n (%) | .9 | ||
| Age of <7 year, no hepatomegaly | 9 (64) | 32 (64) | |
| Age of >7 year, no hepatomegaly; or age of <7 year with hepatomegaly | 4 (29) | 15 (30) | |
| Age of >7 year and hepatomegaly | 1 (7) | 3 (6) | |
| Acute GVHD prophylaxis, n (%) | Calcineurin inhibitor + corticosteroids, 8 (57) | Calcineurin inhibitor + steroids + abatacept, 24 (48) | — |
| Calcineurin inhibitor + steroids + maraviroc, 6 (43) | Calcineurin inhibitor + mycophenolate mofetil + abatacept, 26 (52) |
| . | No abatacept (n = 14) . | Abatacept (n = 50) . | P value . |
|---|---|---|---|
| Age, median (range), y | 7.3 (2-13.8) | 6.5 (2-13) | .5 |
| Preparative regimen, n (%) | |||
| Busulfan/fludarabine/thiotepa | 14 (100) | 50 (100) | 1.0 |
| HLA match, n (%) | .9 | ||
| Full match | 11 (78) | 40 (80) | |
| Single antigen mismatch | 3 (22) | 10 (20) | |
| Donor relation, n (%) | .9 | ||
| Unrelated | 5 (35) | 19 (38) | |
| Related | 9 (65) | 31 (62) | |
| Stem cell source, n (%) | .9 | ||
| Bone marrow | 12 (85) | 40 (80) | |
| Umbilical cord blood | 1 (7.5) | 0 (0) | |
| Bone marrow + cord blood | 1 (7.5) | 10 (20) | |
| Pre-HSCT median LIC by MRI T2∗ (range), μg/g | 4471 (1658-6800) | 4395 (1666-9742) | .7 |
| Risk stratification, n (%) | .9 | ||
| Age of <7 year, no hepatomegaly | 9 (64) | 32 (64) | |
| Age of >7 year, no hepatomegaly; or age of <7 year with hepatomegaly | 4 (29) | 15 (30) | |
| Age of >7 year and hepatomegaly | 1 (7) | 3 (6) | |
| Acute GVHD prophylaxis, n (%) | Calcineurin inhibitor + corticosteroids, 8 (57) | Calcineurin inhibitor + steroids + abatacept, 24 (48) | — |
| Calcineurin inhibitor + steroids + maraviroc, 6 (43) | Calcineurin inhibitor + mycophenolate mofetil + abatacept, 26 (52) |